---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-004414"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2022-03-23T23:59:59+00:00"
generated_at: "2026-06-26T20:09:54.790853+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tenaya reports FY2021 net loss $72.7M; cash runway into H2 2023; three programs advancing

## Summary
- Cash, equivalents and investments $251.3M at Dec 31, 2021 vs $128.5M year-end 2020; runway to H2 2023.
- R&D expenses $54.4M in FY2021 (up from $31.1M); G&A $18.4M (up from $7.8M).
- Net loss $72.7M ($4.10/share) vs $38.4M ($39.50/share) in 2020.
- TN-201 IND submission for MYBPC3 HCM expected H2 2022; TN-301 IND H2 2022; TN-401 IND in 2023.
- Appointed Sunita Sethi (SVP Regulatory) and Naymisha Patel (SVP Quality); cGMP facility in Union City to be operational H1 2022.

## SEC filing metadata
- accession: 0000950170-22-004414
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2022-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017022004414/0000950170-22-004414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017022004414/tnya-20220323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-004414
- JSON: https://secwatch.observer/filing/0000950170-22-004414.json
- Plain text: https://secwatch.observer/filing/0000950170-22-004414.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.